Oncolytics Biotech Inc. Achieves Nasdaq Compliance Milestone
Oncolytics Biotech Inc. (Nasdaq: ONCY), a pioneering clinical-stage company that specializes in innovative immunotherapy for cancer treatment, has received a significant update regarding its stock compliance status. After previously facing potential delisting, Oncolytics has successfully regained compliance with the minimum bid price requirement mandated by Nasdaq.
Understanding the Compliance Situation
The company received a formal notice from Nasdaq’s Listing Qualifications Department indicating that it met the necessary criteria regarding its common shares. Specifically, this compliance demonstrates that Oncolytics' stock has maintained a closing bid price of at least $1.00 per share for the specified period of 10 consecutive business days. This milestone is crucial for maintaining trading on the Nasdaq Capital Market under the ticker symbol "ONCY."
History Leading to Compliance
Earlier this year, Oncolytics was alerted by Nasdaq about the failure to uphold the required minimum bid price, which is set at US$1.00 for 30 consecutive days. The recent Compliance Notice confirms that the Company addressed this issue effectively, with share prices reaching above this threshold from early July through late July. This achievement allows Oncolytics to continue its operations without interruption and reassures investors of its stability in the market.
About Oncolytics Biotech Inc.
As an innovative biotechnology entity, Oncolytics is at the forefront of developing a unique immunotherapeutic agent, pelareorep, delivered intravenously. This compound has shown promising results in clinical trials, particularly in the treatment of metastatic breast cancer and pancreatic cancer. Not only does pelareorep stimulate anti-cancer immune responses, but it also enhances the immune system’s ability to target and attack tumors effectively, thereby redefining treatment methodologies for various cancer types.
Clinical Trials and Future Directions
Oncolytics is actively conducting clinical trials that test the efficacy of pelareorep in combination with existing oncology therapies. The Company is making headway with registrational trials in the aforementioned cancer types and has received Fast Track designation from regulatory bodies, paving the way for potential breakthroughs in treatments.
Enhancing Patient Outcomes
The aim of Oncolytics is clear: to advance effective cancer treatments that improve patient outcomes and quality of life. By transforming immunotherapy strategies and efficiently incorporating pelareorep into treatment regimens, Oncolytics seeks to provide renewed hope to patients facing challenging diagnoses.
Company Values and Community Engagement
At its core, Oncolytics values not only innovative research but also a commitment to engagement with the larger healthcare community. This involves sharing important updates, developments, and breakthroughs, while maintaining transparency with stakeholders.
Conclusion
Regaining compliance with Nasdaq listing standards marks a significant turning point for Oncolytics Biotech Inc. The Company remains steadfast in its mission to innovate cancer treatment, offering new avenues of hope for patients. As it progresses toward clinical advancements, Oncolytics continues to solidify its reputation as a leader in biotechnology and cancer care.
Frequently Asked Questions
What does being in compliance with Nasdaq mean for Oncolytics?
Being in compliance means that Oncolytics has met the necessary stock price requirements to continue trading on the Nasdaq, showing stability and investor confidence.
What is pelareorep?
Pelareorep is an intravenous immunotherapeutic agent under development by Oncolytics, which has shown promise in treating various cancers, including breast and pancreatic cancers.
What are the benefits of Fast Track designation?
Fast Track designation accelerates the review process by regulatory authorities, enabling quicker access to promising treatments for patients and potential market entry.
How is Oncolytics contributing to cancer treatment research?
Oncolytics conducts clinical trials to explore the effectiveness of pelareorep combined with existing treatments, advancing new solutions in oncology.
Who can I contact for more information about Oncolytics?
For inquiries, you may reach out to Jon Patton, the Director of IR & Communication, or Mike Moyer at LifeSci Advisors for investor relations.
